-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] According to news on June 21, the pharmaceutical e-commerce sector has ris.
From the perspective of individual stocks, Huarui shares rose by more than 12%, Xinhua Pharmaceuticals rose by more than 9%, and Zuoli Pharmaceutical, Baheal Pharmaceuticals , Nanjing Medicine, Luyan Medicine, e.
followed .
Among them, as of 10:38, Huarui's share price was quoted at 57 yuan, the turnover was 208 million, the turnover rate was 74%, and the price-earnings (TTM) was 40The company recently said in an institutional survey that the current OTC and Internet accounts account for about 1
The company will increase market coverage including retail pharmacies and online e-commerce channels to improve the accessibility of consumers to purchase dru.
As of 10:38, the quotation of Xinhua Pharmaceutical was 282 yuan, the turnover was 981 billion, the turnover rate was 112%, and the price-earnings (TTM) was 59In the news, the company recently signed a "Strategic Cooperation Agreement" with Real Biology, and Real Biology agreed to Xinhua Pharma to be the product manufacturer and distributor of Azvudine and other products it owns in China and other countries agreed by both parti.
Pharmaceutical e-commerce is an important part of China's national economy, and it is an industry that combines traditional industries and Internet econo.
Pharmaceutical e-commerce can be divided into pharmaceutical B2B (business-to-business, such as Pharmacist Gang), B2C (business-to-customer, such as Ali Health, JD Health) and O2O (online-to-offline, such as Dingdang Kuaiyao, .
com Expres.
Many of these Internet pharmaceutical companies have multiple mode.
In recent years, with the vigorous development of the Internet, the popularization of informatization, and the demographic dividend, the pharmaceutical e-commerce industry has developed rapid.
Especially since 2020, the public has gradually accepted online consultations and online drug purchases, accelerated the promotion of medical insurance to pay for Internet diagnosis and treatment, and brought a period of rapid development to pharmaceutical e-commer.
According to data from Min.
com, in 2021, the sales of terminal drugs (chemical drugs + proprietary Chinese medicines) in China's online pharmacies will exceed 30 billion yuan, a year-on-year increase of more than 5
Among them, prescription drug sales account for half of the pharmaceutical e-commer.
Entering 2022, relevant data shows that from January to April 2022, the national pharmaceutical e-commerce B2C market size is 41 billion yuan, a year-on-year increase of about 2
However, the industry generally believes that with the Internet covering the entire population, the Internet traffic dividend will end, and the overall pharmaceutical e-commerce market will slow down, which will force pharmaceutical e-commerce companies to actively transfo.
Among them, refinement will become one of the key factors for the success of pharmaceutical e-commerce transformati.
In addition, in March this year, China issued the "Internet Diagnosis and Treatment Supervision Rules (Trial)" (hereinafter referred to as the "Trial Rules"), which clearly states that patients should provide medical records with a clear diagnosis, such as outpatient medical records, inpatient medical records, discharge summary, diagnosis Certificates, e.
, the receiving physician will retain the relevant information and determine whether it meets the conditions for follow-up consultati.
Internet diagnosis and treatment medical records shall be managed in accordance with the relevant regulations on outpatient electronic medical records, and shall be kept for at least 15 yea.
The record keeping period of graphic dialogues, audio and video materials and other process records in diagnosis and treatment shall not be less than 3 yea.
At the same time, the prescription should be issued by the receiving physician himself, and the use of artificial intelligence to automatically generate prescriptions is strictly prohibit.
Prescription drugs shall be sold, dispensed and used under the prescription of a physici.
It is strictly prohibited to provide a drug to a patient before a prescription has been issu.
At the same time, the rules make it clear that "it is strictly forbidden to unify prescriptions for commercial purposes", "it is strictly forbidden to refer patients for the purpose of seeking profits, and to designate places to purchase medicines and consumabl.
This document is considered by the industry to be a major blow for pharmaceutical e-commerce, and the entire industry will enter an era of strong supervisi.
In this regard, some analysts believe that under this background, the industry will enter a period of pain, and some small and medium-sized enterprises that do not have the conditions Pharmaceutical e-commerce companies may not survive, but there are still opportunities for leading compani.
Click to enter the exhibition page
From the perspective of individual stocks, Huarui shares rose by more than 12%, Xinhua Pharmaceuticals rose by more than 9%, and Zuoli Pharmaceutical, Baheal Pharmaceuticals , Nanjing Medicine, Luyan Medicine, e.
followed .
Among them, as of 10:38, Huarui's share price was quoted at 57 yuan, the turnover was 208 million, the turnover rate was 74%, and the price-earnings (TTM) was 40The company recently said in an institutional survey that the current OTC and Internet accounts account for about 1
The company will increase market coverage including retail pharmacies and online e-commerce channels to improve the accessibility of consumers to purchase dru.
As of 10:38, the quotation of Xinhua Pharmaceutical was 282 yuan, the turnover was 981 billion, the turnover rate was 112%, and the price-earnings (TTM) was 59In the news, the company recently signed a "Strategic Cooperation Agreement" with Real Biology, and Real Biology agreed to Xinhua Pharma to be the product manufacturer and distributor of Azvudine and other products it owns in China and other countries agreed by both parti.
Pharmaceutical e-commerce is an important part of China's national economy, and it is an industry that combines traditional industries and Internet econo.
Pharmaceutical e-commerce can be divided into pharmaceutical B2B (business-to-business, such as Pharmacist Gang), B2C (business-to-customer, such as Ali Health, JD Health) and O2O (online-to-offline, such as Dingdang Kuaiyao, .
com Expres.
Many of these Internet pharmaceutical companies have multiple mode.
In recent years, with the vigorous development of the Internet, the popularization of informatization, and the demographic dividend, the pharmaceutical e-commerce industry has developed rapid.
Especially since 2020, the public has gradually accepted online consultations and online drug purchases, accelerated the promotion of medical insurance to pay for Internet diagnosis and treatment, and brought a period of rapid development to pharmaceutical e-commer.
According to data from Min.
com, in 2021, the sales of terminal drugs (chemical drugs + proprietary Chinese medicines) in China's online pharmacies will exceed 30 billion yuan, a year-on-year increase of more than 5
Among them, prescription drug sales account for half of the pharmaceutical e-commer.
Entering 2022, relevant data shows that from January to April 2022, the national pharmaceutical e-commerce B2C market size is 41 billion yuan, a year-on-year increase of about 2
However, the industry generally believes that with the Internet covering the entire population, the Internet traffic dividend will end, and the overall pharmaceutical e-commerce market will slow down, which will force pharmaceutical e-commerce companies to actively transfo.
Among them, refinement will become one of the key factors for the success of pharmaceutical e-commerce transformati.
In addition, in March this year, China issued the "Internet Diagnosis and Treatment Supervision Rules (Trial)" (hereinafter referred to as the "Trial Rules"), which clearly states that patients should provide medical records with a clear diagnosis, such as outpatient medical records, inpatient medical records, discharge summary, diagnosis Certificates, e.
, the receiving physician will retain the relevant information and determine whether it meets the conditions for follow-up consultati.
Internet diagnosis and treatment medical records shall be managed in accordance with the relevant regulations on outpatient electronic medical records, and shall be kept for at least 15 yea.
The record keeping period of graphic dialogues, audio and video materials and other process records in diagnosis and treatment shall not be less than 3 yea.
At the same time, the prescription should be issued by the receiving physician himself, and the use of artificial intelligence to automatically generate prescriptions is strictly prohibit.
Prescription drugs shall be sold, dispensed and used under the prescription of a physici.
It is strictly prohibited to provide a drug to a patient before a prescription has been issu.
At the same time, the rules make it clear that "it is strictly forbidden to unify prescriptions for commercial purposes", "it is strictly forbidden to refer patients for the purpose of seeking profits, and to designate places to purchase medicines and consumabl.
This document is considered by the industry to be a major blow for pharmaceutical e-commerce, and the entire industry will enter an era of strong supervisi.
In this regard, some analysts believe that under this background, the industry will enter a period of pain, and some small and medium-sized enterprises that do not have the conditions Pharmaceutical e-commerce companies may not survive, but there are still opportunities for leading compani.
Click to enter the exhibition page
